Clinic Software← All companies
GlycoX
A groundbreaking food ingredient that harnesses nature’s power with scientific precision to deliver reliable blood-sugar control—straight from your plate.
health AI / medtech / digital health (startup focused on metabolic health and glycemic control)
StageEarly Stage VC
Raised$300K
Founded2024
Employees3
LocationDelaware, DE
Business modelB2B2C / SaaS-like integration of a functional ingredient into products (ingredient platform)
About
At GlycoX, we’re building a new generation of oral metabolic solutions that help the body regain its natural balance. Our first product targets healthy, lasting weight loss — reducing fat while preserving muscle. Our second focuses on rapid, insulin-independent glucose control to improve metabolic health in diabetes and prediabetes. Together, they form the foundation of our mission: to make true metabolic health accessible, sustainable, and empowering.
Product
- Value proposition
- Science-backed, scalable solution that normalizes blood sugar and supports metabolic resilience without needles or surgery.
- Target customers
- Consumer brands, food and beverage companies, healthcare providers seeking metabolic health solutions
- Pricing
- not explicitly stated; likely B2B2C with ingredient licensing or per-application pricing
Founders
- Matias Gonzalez — CEO and Co-founder
- Lais Tonello — COO and Co-founder
- Robson Olivoto — CSO and Co-founder
Categories
Products
GlycoX ingredient platform (functional food ingredient)
Key features
sangre glucose normalization supportantioxidant and anti-inflammatory supportscalable, science-backed formulationeasy to integrate into daily routines
Technologies
plant-derived bioactivescontrolled natural variable refinementbioactives optimization
Integrations
EHRs / platforms / systems could be integrated via product partnerships (not explicit)
Target conditions
glycemic dysregulationpre-diabetestype 2 diabetes riskmetabolic syndrome
Care settings
homeclinical research settings
Certifications
HIPAA (not directly applicable to ingredient company)FDA status: not stated / regulatory pathway not disclosed
Partnerships
WeArePalta (mentioned in extras)
Traction metrics
global metabolic dysfunction context described; not specific traction metrics
Investors
Grid ExponentialAIR Capital
News
- LvlUp Ventures June 22 Companies Backed - LinkedIn · 2026-06-22T00:00:00.000Z
- Glycyx Awarded NIH SBIR Phase 2 Grant to Advance Axelopran and Pembrolizumab Study in Head and Neck Cancer · 2025-09-26T05:20:32.000Z
